MMAF

CAT: 0804-HY-15579-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15579-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A[1][2][3].
CAS Number
[745017-94-1]
Product Name Alternative
Monomethylauristatin F
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
ADC Payload; Microtubule/Tubulin
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mmaf.html
Purity
99.97
Solubility
DMSO : 140 mg/mL (ultrasonic)
Smiles
CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O
Molecular Formula
C39H65N5O8
Molecular Weight
731.96
Precautions
H302, H315, H319, H335
References & Citations
[1]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17 (1) :114-24.|[2]Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16 (9) :2562-70.|[3]Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54 (41) :12020-4.|[4]Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Auristatin
Citation 01
J Control Release. 2018 May 10;277:48-56.|Mol Cancer Ther. 2023 Apr 3;22 (4) :459-470.|Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236.|Patent. US20210393733A1.|Research Square Preprint. 2023 Dec 4.|Research Square Print. 2023 Jan 6th.|Target Oncol. 2019 Oct;14 (5) :577-590.|University of Minnesota. 2022 Sep.|Oncol Rep. 2021 Feb;45 (2) :776-785.

Related Products

CatalogName
HY-W100249-01MMAI
HY-15581-01MMAD
HY-135222MMAI (hydrochloride)
HY-171572-01Atezolizumab-MMAE
HY-171269Anetumab-MMAE
HY-171135-01Cetuximab MMAE
HY-15740-01Mc-MMAD
HY-156712-01Depatuxizumab MMAE
HY-15581S-01MMAD-d8
HY-78933-01Fmoc-MMAE

Alternative Products

CatalogName
B3270-10MMAF
M16260-01MMAF-OMe
456397MMAF Hydrochloride
MBS5799756DBM-MMAF
BA2356-5MMAF-OtBu
MF-0121656-01NHS-MMAF
MBS5766443D8-MMAF
MBS5755220MMAF sodium
MBS130308-01MMAF-Hydrochloride
MF-0154594-01Modified MMAF

Popular Products